Influenza Virus Vaccine USP Trivalent Types A and B

BIOLOGICAL3 trials

Sponsors

Sanofi Pasteur, a Sanofi Company

Conditions

InfluenzaMyxovirus InfectionOrthomyxoviridae InfectionOrthomyxovirus Infection

Phase 2

Influenza Vaccine Revaccination in Ambulatory Elderly Subjects

CompletedNCT00775450

Sanofi Pasteur, a Sanofi CompanyInfluenza, Myxovirus Infection, Orthomyxovirus Infection

Start: 2008-10-31End: 2009-07-31Updated: 2013-12-31

Study of Influenza Vaccine Revaccination in Healthy Adults Previously Vaccinated With Fluzone ID or Fluzone IM

CompletedNCT01011049

Sanofi Pasteur, a Sanofi CompanyInfluenza

Start: 2009-09-30End: 2010-10-31Updated: 2016-04-14

Phase 3

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

CompletedNCT00772109

Sanofi Pasteur, a Sanofi CompanyInfluenza, Myxovirus Infection, Orthomyxoviridae Infection

Start: 2008-10-31End: 2009-07-31Updated: 2016-04-14

Related Papers

Safety and immunogenicity of revaccination with reduced dose intradermal and standard dose intramuscular influenza vaccines in adults 18-64 years of age.

2013-09-2017 citations

Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.

2013-03-1330 citations